Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of Earliest Event Reported):   March 17, 2014


STAAR Surgical Company


(Exact name of registrant as specified in its charter)


Delaware 0-11634 95-3797439
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
1911 Walker Ave, Monrovia, California   91016
(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code:   626-303-7902


Not Applicable




Former name or former address, if changed since last report


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 7.01 Regulation FD Disclosure.


STAAR Surgical Company’s President and Chief Executive Officer, Barry Caldwell, will give presentations to investors in New York on March 17, 2014. A copy of the slide presentation Mr. Caldwell will use in his presentation is furnished as Exhibit 99.1 to this Report, and is incorporated herein by this reference.


The information furnished herewith pursuant to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.


Item 8.01 Other Events.


On March 17, 2014, STAAR Surgical Company issued a News Release announcing the results of the March 14, 2014 FDA Ophthalmic Medical Device Committee’s advisory meeting, which among other things voted favorably that the benefits of the Visian Toric ICL outweigh the risks in patients who meet the criteria specified in the proposed indication. A copy of the News Release is furnished as Exhibit 99.2 to this current report.        


Item 9.01 Financial Statements and Exhibits




Exhibit No. Description
99.1 Slide Presentation dated March 17, 2014.
99.2 News Release, dated March 17, 2014, announcing the results of the March 14, 2014 FDA Ophthalmic Medical Device Committee’s advisory meeting.





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


STAAR Surgical Company   
March 17, 2014 By:   /s/ Barry G. Caldwell  
    Barry G. Caldwell  
    President and Chief Executive Officer